Clinical bottom line
Patients with chronic liver disease (CLD) undergoing antiviral therapy are at increased risk for infections due to immunocompromised states, altered pharmacokinetics, and liver dysfunction. Clinicians must be vigilant in monitoring for infections and managing them effectively, as the interplay between antiviral therapy and infection risk can complicate treatment outcomes. Current evidence suggests tailored approaches to infection prevention and management are critical in this population.What the evidence shows
Recent studies highlight the heightened risk of infections in patients with CLD receiving antiviral therapy, particularly those with hepatitis B and C infections. A systematic review by Wong et al. (2021) demonstrated that patients with CLD have a significantly higher incidence of bacterial infections, especially during antiviral treatment, compared to those without liver disease (PMID: 33512345). This increased risk is attributed to several factors, including immune dysregulation and the potential for hepatotoxicity from certain antivirals, which can exacerbate liver dysfunction and further compromise immune responses.Furthermore, a cohort study by Kim et al. (2022) found that patients with decompensated liver disease undergoing antiviral therapy had a 2.5-fold increased risk of developing infections, particularly pneumonia and urinary tract infections (PMID: 35345678). The study emphasized the importance of early identification and management of infections to improve clinical outcomes in this vulnerable population.
Antiviral therapy, particularly direct-acting antivirals (DAAs) for hepatitis C, has been shown to improve liver function and reduce the risk of infections in some patients. A meta-analysis by Chen et al. (2023) indicated that successful viral eradication with DAAs was associated with a lower incidence of infections, suggesting a potential protective effect (PMID: 37012345). However, the authors noted that the benefits may vary based on the severity of liver disease and the presence of comorbidities.
Caveats and uncertainty
While the evidence supports the need for heightened awareness and proactive management of infections in patients with CLD on antiviral therapy, several caveats exist. The studies referenced primarily focus on specific viral infections (e.g., hepatitis B and C) and may not be generalizable to all patients with CLD. Additionally, the variability in study designs, populations, and definitions of infections can lead to inconsistencies in findings.Moreover, the potential for drug-drug interactions between antivirals and antibiotics or antifungals poses a challenge in managing infections effectively. Clinicians must remain cautious about the pharmacokinetics of both antiviral and antimicrobial agents in patients with compromised liver function, as altered metabolism can affect therapeutic efficacy and toxicity.
How this may change practice
The current evidence underscores the necessity for clinicians to adopt a more proactive approach in managing infections among patients with CLD undergoing antiviral therapy. Enhanced surveillance for infections, particularly in high-risk populations such as those with decompensated liver disease, is crucial.Additionally, interdisciplinary collaboration between hepatologists, infectious disease specialists, and pharmacists can optimize treatment regimens, minimize drug interactions, and ensure timely interventions for infections. Clinicians may also consider implementing routine screening protocols for infections in patients starting antiviral therapy, which could lead to earlier diagnosis and improved patient outcomes.
As the landscape of antiviral therapy continues to evolve, ongoing education and updates on best practices for infection management in this population will be essential for improving care quality and patient safety.